Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study
Qi Li(First Affiliated Hospital of Xi'an Jiaotong University), Zhaohui Tang(Shanxi Agricultural University), Yinghe Qiu(Second Military Medical University), Yu He(Southern University of Science and Technology), Tianqiang Song(Tianjin Medical University Cancer Institute and Hospital), Jingbo Su(Xijing Hospital), Xianhai Mao(Hunan Provincial People's Hospital), Hong Wu(Sichuan University), Zhangjun Cheng(Zhongda Hospital Southeast University), Dong Zhang(Capital Medical University), Jingdong Li(Sun Yat-sen University), Zhimin Geng(Children's Hospital of Zhejiang University), Chen Chen(First Affiliated Hospital of Xi'an Jiaotong University), Wenlong Zhai(Zhengzhou University)
Cited by 19
Related Papers
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer
|Molecular Cancer|2022|652
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial
|The Lancet. Gastroenterology & hepatology|2021|268